Denali Therapeutics Inc.
Substituted pyrimidines as LRKK2 inhibitors

Abstract:

The present disclosure relates generally to compounds of formula (I) ##STR00001## or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.